

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Sisram Medical Ltd
復銳醫療科技有限公司*
(Incorporated in Israel with limited liability)
(Stock Code: 1696)

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING
HELD ON 30 NOVEMBER 2021**

Reference is made to the circular (the “**Circular**”) and the notice of the extraordinary general meeting of Sisram Medical Ltd 復銳醫療科技有限公司* (the “**Company**”) dated 26 October 2021. Unless otherwise defined in this announcement, terms used herein shall have the same meanings as ascribed to them in the Circular.

At the extraordinary general meeting (the “**EGM**”) of the Company held on 30 November 2021, all the proposed resolutions as set out in the notice of the EGM dated 26 October 2021 were taken by poll. The poll results are as follows:

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
1.	To consider and, if thought fit, approve the proposed adoption of the 2021 RSU Scheme and the grant of a specific mandate to the Directors of the Company to issue and allot up to 22,107,780 Shares upon vesting of the RSUs to be granted under the 2021 RSU Scheme (the “ RSU Scheme Annual Mandate ”).	253,756,330 (97.942116%)	5,331,731 (2.057884%)	40 (–)
2.	To consider and, if thought fit, approve the proposed adoption of the Remuneration Policy for Directors and Officers.	253,756,330 (97.942116%)	5,331,731 (2.057884%)	40 (–)
3.	To consider and, if thought fit, approve the proposed grant of 220,000 RSUs to Mr. Yi LIU, Chairman and executive Director of the Company, in accordance with the terms of the 2021 RSU Scheme and the issue of corresponding number of Shares to Mr. Yi LIU upon vesting of the RSUs.	254,351,130 (99.747395%)	644,131 (0.252605%)	4,092,840 (–)
4.	To consider and, if thought fit, approve the proposed grant of 800,000 RSUs to Mr. Lior Moshe DAYAN, an executive Director and the Chief Executive Officer of the Company, in accordance with the terms of the 2021 RSU Scheme, and the issue of corresponding number of Shares to Mr. Lior Moshe DAYAN upon vesting of the RSUs.	254,351,130 (99.747395%)	644,131 (0.252605%)	4,092,840 (–)
5.	To consider and, if thought fit, approve the proposed grant of 80,000 RSUs to Mr. Guojun BU, an executive Director and the Chief Financial Officer of the Company, in accordance with the terms of the 2021 RSU Scheme, and the issue of corresponding number of Shares to Mr. Guojun BU upon vesting of the RSUs.	254,351,530 (99.747552%)	643,731 (0.252448%)	4,092,840 (–)

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Abstain
6.	To consider and, if thought fit, approve the proposed grant of 183,490 RSUs to Mr. Doron YANNAI, a vice president of the Company and a director of the Company's subsidiaries, in accordance with the terms of the 2021 RSU Scheme, and the issue of corresponding number of Shares to Mr. Doron YANNAI upon vesting of the RSUs.	254,351,530 (99.747552%)	643,731 (0.252448%)	4,092,840 (-)

Notes:

- (a) Under the Israeli Companies Law, the resolutions numbered 2 and 4 will also need to be approved in each case by either (i) majority of Shareholders, who attend the EGM in person or through proxy and who are unrelated to the Company's controlling shareholders and don't have a personal interest, but excluding the Shareholders who have abstained from voting at the EGM, or (ii) a simple majority of Shareholders, including controlling Shareholders and Shareholders with personal interest, who attend the EGM in person or through proxy, provided that votes against the resolutions do not exceed 2% of the total issued and outstanding shares of the Company. As condition (i) has also been satisfied, the relevant resolutions were duly passed as ordinary resolutions.
- (b) As a majority of the votes were cast in favour of the resolutions numbered 1, 3, 5 and 6, all resolutions were duly passed as ordinary resolutions.
- (c) As at the date of the EGM, the total number of Shares in issue was 466,155,600 shares, which is the total number of Shares entitling the Shareholders to attend and vote on the resolutions at the EGM.
- (d) There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the resolutions at the EGM as set out in rule 13.40 of the Listing Rules.
- (e) 113,500 Shares held by Mr. Lior Moshe DAYAN were required under the Listing Rules to abstain from voting and have abstained from voting on the resolution numbered 4 at the EGM.
- (f) None of the Shareholders has stated his/her intention in the Circular to vote against or to abstain from voting on the resolutions numbered 1 to 6 at the EGM.
- (g) The Company's Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the EGM.

By Order of the Board
Sisram Medical Ltd
復銳醫療科技有限公司*
Yi LIU
Chairman

Hong Kong, 30 November 2021

As at the date of this announcement, the board of directors of the Company comprises Mr. Yi LIU, Mr. Lior Moshe DAYAN and Mr. Guojun BU as executive directors; Mr. Yifang WU, Mr. Yao WANG and Ms. Rongli FENG as non-executive directors; Mr. Heung Sang Addy FONG, Mr. Chi Fung Leo CHAN, Ms. Jenny CHEN and Mr. Kai Yu Kenneth LIU as independent non-executive directors.

* For identification purpose only